CW 008

| Cat. No.: | HY-110218 | | | |
|--------------------|--|-------|----------|--|
| CAS No.: | 1134613-19-6 | | | |
| Molecular Formula: | C ₂₁ H ₁₄ F ₂ N ₆ O ₂ | | | |
| Molecular Weight: | 420.37 | | | |
| Target: | PKA; Epigenetic Reader Domain | | | |
| Pathway: | Stem Cell/Wnt; TGF-beta/Smad; Epigenetics | | | |
| Storage: | Powder | -20°C | 3 years | |
| | In solvent | -80°C | 6 months | |
| | | -20°C | 1 month | |

SOLVENT & SOLUBILITY

In Vitro DMSO: 16.67 mg/mL (39.66 mM; ultrasonic and warming and heat to 60°C) Mass Solvent 10 mg 1 mg 5 mg Concentration Preparing 2.3789 mL 11.8943 mL 23.7886 mL 1 mM **Stock Solutions** 5 mM 0.4758 mL 2.3789 mL 4.7577 mL 0.2379 mL 2.3789 mL 10 mM 1.1894 mL Please refer to the solubility information to select the appropriate solvent.

| BIOLOGICAL ACTI | VITY |
|-----------------|---|
| Description | CW 008, a derivative of pyrazole-pyridine, is a CREB or PKA pathway agonist. CW 008 also is a stem cell differentiating agent. CW 008 stimulates osteoblast differentiation of human MSCs and increases bone formation in ovariectomized mice. CW008 promotes osteogenesis by activating cAMP/PKA/CREB signaling pathway and inhibiting leptin secretion ^{[1][2][3]} . |
| IC₅₀ & Target | РКА |

REFERENCES

[1]. Nooshin AMINI, et al. Methods and compositions for generating human forebrain neural progenitor cells and for maturation thereof to parvalbumin+ interneurons. Patent, WO2023075913A1.

[2]. Patrick Soon-Shiong. Patient treatment via teratogenic pharmaceutical compounds. Patent, WO2016176675A2.

[3]. Kim JM, et al. An activator of the cAMP/PKA/CREB pathway promotes osteogenesis from human mesenchymal stem cells. J Cell Physiol. 2013 Mar;228(3):617-26.

Inhibitors

•


Screening Libraries

•

Proteins







Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA